Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
TScan Therapeutics, Inc. (NASDAQ: TCRX) is a clinical-stage biopharmaceutical company focused on developing a pipeline of T-cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. TScan is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The company utilizes its proprietary TargetScan platform to identify novel, shared TCR targets and develop corresponding TCRs for therapeutic applications.
The headquarters serves as the central hub for TScan's research and development activities, clinical operations, corporate strategy, and administrative functions.
The facility likely includes state-of-the-art laboratory spaces for immunology, molecular biology, and cell therapy process development, alongside modern office environments.
As a clinical-stage biotech, the work culture is likely characterized by innovation, scientific rigor, collaboration, a fast-paced environment, and a strong focus on advancing therapies for patients with cancer.
Its location in Waltham provides strategic advantages, including access to a rich talent pool from nearby academic institutions and other biotech companies, proximity to collaborators, and a supportive life sciences ecosystem.
TScan Therapeutics is primarily focused on its operations within the United States, with its research, development, and corporate activities centralized at its Waltham, MA headquarters. While direct international offices are not prominent, its clinical trials may involve sites and collaborators globally as its therapeutic candidates advance. The company's engagement with the international scientific and medical community also contributes to its global reach in the field of cancer immunotherapy.
830 Winter Street
Waltham
Massachusetts
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, TScan Therapeutics' leadership includes:
TScan Therapeutics has been backed by several prominent investors over the years, including:
Over the past year, TScan Therapeutics has strengthened its leadership team with key appointments, particularly in finance and people operations, to support its growth and clinical development programs.
Discover the tools TScan Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
TScan Therapeutics most likely utilizes a common corporate email format. The most probable pattern is the first initial followed by the last name, or first name dot last name.
[first_initial][last]@tscan.com
Format
jdoe@tscan.com
Example
80%
Success rate
GlobeNewswire • March 7, 2024
TScan Therapeutics reported its financial results for Q4 and full year 2023, highlighting progress in its clinical programs and outlining upcoming milestones for its TCR-T therapies....more
GlobeNewswire • February 22, 2024
TScan presented promising initial data from its Phase 1 study of TSC-100 and TSC-101 in patients with hematologic malignancies, showing early signs of efficacy and tolerability....more
GlobeNewswire • January 4, 2024
TScan announced the promotion of Heather Maines, Ph.D., to the newly created role of Chief People Officer and Head of Portfolio Strategy, strengthening its executive leadership team....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including TScan Therapeutics, are just a search away.